High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary?

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1561-1567

  Glantz, Michael J ^a   Cole, Bernard F ^a   Recht, Lawrence ^a   Akerley, Wallace ^a   Mills, Pam ^a   Saris, Stephen ^a   Hochberg, Fred ^a   Calabresi, Paul ^a   Egorin, Merrill J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE; ONDANSETRON;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; STOMATITIS;

EID: 0031923886     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1561     Document Type: Article

References (61)

1. Hitchins RN, Bell DR, Woods RL, et al: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655-1662, 1987
2. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 49:759-772, 1982
3. Bleyer WA, Poplack DG: Intraventricular versus intralumbar methotrexate for central nervous system leukemia: Prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 6:207-213, 1979
4. Shapiro WR, Posner JB, Ushio Y, et al: Treatment of meningeal neoplasms. Cancer Treat Rep 61:733-743, 1977
5. Glantz MJ, Hall WH, Cole BF, et al: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:2919-2931, 1995
6. 111Indium-DTPA CSF flow studies. Neurology 41:1765-1769, 1991
7. 111indium-DTPA ventriculography. Am J Med 73:641-647, 1982
8. Balm M, Hammack J: Leptomeningeal carcinomatosis: Presenting features and prognostic factors. Arch Neurol 53:626-632, 1996
9. Fizazi K, Asselain B, Vincent-Salomon A, et al: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77:1315-1323, 1996
10. Grant R, Naylor B, Greenberg HS, et al: Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 51:457-461, 1994
11. Jayson GE, Howell A, Harris M, et al: Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 74:3135-3141, 1994
12. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: Analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 4:1463-1469, 1994
13. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11:561-569, 1993
14. Boogerd W, Hart AAM, van der Sande JJ, et al: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67:1685-1695, 1991
15. Lishner M, Perrin RG, Feld R, et al: Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 150:173-176, 1990
16. Perrin RG, Lishner M, Guha A, et al: Experience with Ommaya reservoir in 120 consecutive patients with meningeal malignancy. Can J Neurol Sci 17:190-192, 1990
17. Lemann W, Wiley RG, Posner JB: Leukoencephalopathy complicating intraventricular catheters: Clinical, radiographic and pathologic study of 10 cases. J Neurooncol 6:67-74, 1988
18. Browne MJ, Dinndorf PA, Perek D, et al: Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J 6:182-189, 1987
19. Obbens EAMT, Leavens ME, Beal JW, et al: Ommaya reservoirs in 387 cancer patients: A 15-year experience. Neurology 35:1274-1278, 1985
20. Cher L, Glass J, Harsh GR, et al: Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology 46:1757-1759, 1996
21. McCowage G, Tien R, McLendon R, et al: Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Med Pediatr Oncol 27:32-39, 1996
22. Yeh KH, Cheng AL, Tien HF: Primary T cell leptomeningeal lymphoma - Successful treatment with systemic chemotherapy. Oncology 52:501-504, 1995
23. Mencel PJ, DeAngelis LM, Motzer RJ: Hormonal ablation is effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 73:1892-1894, 1994
24. van der Graaf WT, Haaxma-Reiche H, Burghouts JT, et al: Teniposide for meningeal carcinomatosis of small-cell lung cancer. Lung Cancer 10:247-249, 1993
25. Balis FM, Savitch JL, Bleyer WA, et al: Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 3:485-489, 1985
26. Pignon T, Lacarelle B, Duffaud F, et al: Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 33:420-424, 1994
27. Glantz MJ, Cole BF, Glantz LK, et al: Cerebrospinal fluid cytology in patients with cancer. Minimizing false-negative results. Cancer 82:733-739, 1998
28. Laird NM, Ware JH: Random effects models for longitudinal data. Biometrics 38:963-974, 1982
29. Kim S, Khatibi S, Howell SB, et al: Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 53:1596-1598, 1993
30. Balis F, Poplack D: Central nervous system pharmacology of antileukemic drugs. Amer J Pediatr Hemat Oncol 11:74-86, 1989
31. Strong J, Collins J, Lester C, et al: Pharmacokinetics of intraventricular and intravenous N,N′,N″-Triethylenethiophosphoramide (Thiotepa) in Rhesus monkeys and humans. Cancer Res 46:6101-6104, 1986
32. Slevin M, Piall E, Aherne G, et al: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1:546-551, 1983
33. Chamberlain MC: New approaches to and current treatments of leptomeningeal metastases. Curr Opin Neurol 7:492-500, 1994
34. Pfeffer MR, Wygoda M, Siegal T: Leptomeningeal metastases -Treatment results in 98 consecutive patients. Isr J Med Sci 24:611-618, 1988
35. Morra E, Lazzarino M, Brusamolino E, et al: The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 72:439-445, 1993
36. Fulton DS, Levin VA, Gutin PH, et al: Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 8:285-291, 1982
37. Pollack IF, Hurtt M, Pang D, et al: Dissemination of low-grade intracranial astrocytomas in children. Cancer 73:2671-2673, 1994
38. Bruggers CS, Friedman HS, Phillips PC, et al: Leptomeningeal dissemination of optic pathway gliomas in three children. Am J Ophthalmol 111:719-723, 1991
39. Obana WG, Cogen PH, Davis RL, et al: Metastatic juvenile pilocytic astrocytoma. Case report. J Neurosurg 75:972-975, 1991
40. Trigg ME, Swanson JD, Letellier MA: Metastasis of an optic glioma through a ventriculoperitoneal shunt. Cancer 52:599-601, 1983
41. 2 methotrexate. Leuk Lymph 14:141-144, 1994
42. 2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group. Eur J Cancer 26:492-495, 1990
43. Vassal G, Valteau D, Bonnay M, et al: Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non-Hodgkin's lymphoma. Pediatr Hematol Oncol 7:71-77, 1990
44. Lippens RJ, Winograd B: Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: An unreliable prediction. Pediatr Hematol Oncol 5:115-124, 1988
45. Bode U, Magrath IT, Bleyer WA, et al: Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res 40:2184-2187, 1980
46. Mehta BM, Glass JP, Shapiro WR: Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res 43:435-438, 1983
47. Shapiro WR, Young DF, Mehta BM: Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161-166, 1975
48. Chabner BA, Young R: Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52:1804-1811, 1973
49. Strother DR, Glynn-Barnhart A, Kovnar E: Variability in the disposition of intraventricular methotrexate: A proposal for rational dosing. J Clin Oncol 7:1741-1747, 1989
50. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289:770-773, 1973
51. Bleyer WA, Poplack DG, Simon RM: "Concentration X Time" methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51:835-842, 1978
52. Miller KT, Wilkinson DS: Pharmacokinetics of methotrexate in the cerebrospinal fluid after intracerebroventricular administration in patients with meningeal carcinomatosis and altered cerebrospinal fluid flow dynamics. Ther Drug Monit 11:231-237, 1989
53. 111Indium-DTPA cerebrospinal fluid (CSF) studies in leptomeningeal metastases (LM) predict intrathecal methotrexate (MTX) distribution and response to therapy. Proc Am Soc Clin Oncol 15:155, 1996 (abstr)
54. Ushio Y, Shimizu K, Aragaki Y, et al: Alteration of blood-CSF barrier by tumor invasion into the meninges. J Neurosurg 55:445-449, 1981
55. Ushio Y, Chernik NL, Posner JB, et al: Meningeal carcinomatosis: Development of an experimental model. J Neuropathol Exp Neurol 36:228-244, 1977
56. Siegal T, Sandbank U, Gabizon A, et al: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis: A morphologic and adriamycin-penetration study. J Neurooncol 4:233-242, 1987
57. Nicholas DS, Weller RO: The fine anatomy of the human spinal meninges. A light and scanning electron microscopy study. J Neurosurg 69:276-282, 1988
58. Morse M, Savitch J, Balis F, et al: Altered central nervous system pharmacology of methotrexate in childhood leukemias: Another sign of meningeal relapse. J Clin Oncol 3:19-24, 1985
59. Frank JA, Girton M, Dwyer AJ, et al: Meningeal carcinomatosis in the VX2 rabbit tumor model: Detection with Gd-DTPA-enhanced MR imaging. Radiology 167:825-829, 1988
60. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38:51-57, 1995
61. Chamberlain MC, Sandy AD, Press GA: Leptomeningeal metastases: A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40:435-438, 1990